Related Experiment Video
Updated: May 5, 2026
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
Targeted androgen pathway suppression in localized prostate cancer: a pilot study
Elahe A Mostaghel1, Peter S Nelson, Paul Lange
1Elahe A. Mostaghel, Rachel Hunter Merrill, and Roman Gulati, Fred Hutchinson Cancer Research Center; Elahe A. Mostaghel, Peter S. Nelson, Paul Lange, Daniel W. Lin, William Ellis, Robert Vessella, and Bruce Montgomery, University of Washington; Brett Marck, Alvin M. Matsumoto, and Lawrence D. True, Veterans Affairs Puget Sound Health Care System, Seattle, WA; Mary Ellen Taplin and Philip Kantoff, Dana-Farber Cancer Institute, Harvard Medical School; Steven Balk, Beth Israel Deaconess Medical Center, Boston, MA; and Daniel Tamae and Trevor Penning, University of Pennsylvania, Philadelphia, PA.
Combining androgen synthesis inhibitors with standard therapy significantly reduces prostate androgens and AR signaling in prostate cancer (PCa) patients. Further research is needed for optimal PCa control.
Area of Science:
- Oncology
- Endocrinology
- Urology
Background:
- Androgen receptor (AR) signaling is crucial for prostate cancer (PCa) progression.
- Incomplete ablation of androgens limits the effectiveness of current PCa therapies.
- Novel therapeutic strategies are needed to enhance AR signaling suppression.
Purpose of the Study:
- To evaluate the efficacy of combined CYP17A and 5-α-reductase inhibitors in reducing prostate androgen levels.
- To assess the impact of these combinations on AR signaling and PCa volumes.
- To compare different combination therapies for their effects on androgen suppression.
Main Methods:
- Thirty-five men with intermediate/high-risk localized PCa received goserelin plus dutasteride (ZD), bicalutamide plus dutasteride (ZBD), or bicalutamide, dutasteride, and ketoconazole (ZBDK) for 3 months pre-prostatectomy.
- Control patients received standard combined androgen blockade.
- Primary outcome was tissue dihydrotestosterone (DHT) concentration.
Main Results:
- All experimental arms achieved significantly lower prostate DHT levels compared to controls (P < .001).
- The ZBDK group showed the most significant reduction in serum testosterone and other androgens (P < .05).
- AR signaling and androgen-regulated genes were suppressed in both benign and malignant glands (P < .05), with notable complete or near-complete responses in the ZBDK group.
Conclusions:
- Androgen synthesis inhibitors effectively lower prostate androgen levels beyond standard therapy.
- Despite significant reduction, substantial AR signaling persists, indicating a need for further optimization.
- Tissue-level analysis of steroids and AR signaling is essential for developing improved high-risk PCa treatments.
